Your browser doesn't support javascript.
loading
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
Camidge, D Ross; Lee, Eudocia Q; Lin, Nancy U; Margolin, Kim; Ahluwalia, Manmeet S; Bendszus, Martin; Chang, Susan M; Dancey, Janet; de Vries, Elisabeth G E; Harris, Gordon J; Hodi, F Stephen; Lassman, Andrew B; Macdonald, David R; Peereboom, David M; Schiff, David; Soffietti, Ricardo; van den Bent, Martin J; Wefel, Jeffrey S; Wen, Patrick Y.
Afiliación
  • Camidge DR; Anschutz Medical Campus, University of Colorado, Aurora, CO, USA. Electronic address: ross.camidge@ucdenver.edu.
  • Lee EQ; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Margolin K; Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA.
  • Ahluwalia MS; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH, USA.
  • Bendszus M; Department of Neuroradiology, University of Heidelberg, Heidelberg, Germany.
  • Chang SM; Department of Neurosurgery, University of California, San Francisco, San Francisco, CA, USA.
  • Dancey J; Department of Oncology, Queen's University, Kingston, ON, Canada.
  • de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Netherlands.
  • Harris GJ; Department of Radiology, 3D Imaging Lab, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Lassman AB; Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Columbia University, NY, USA.
  • Macdonald DR; Department of Oncology and Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
  • Peereboom DM; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH, USA.
  • Schiff D; Division of Neuro-Oncology, University of Virginia, Charlottesville, VA, USA.
  • Soffietti R; Department of Neurology/Neuro-Oncology, University of Turin, Turin, Italy.
  • van den Bent MJ; Brain Tumor Institute, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Wefel JS; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Lancet Oncol ; 19(1): e20-e32, 2018 01.
Article en En | MEDLINE | ID: mdl-29304358
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Ensayos Clínicos como Asunto / Selección de Paciente / Determinación de Punto Final / Antineoplásicos Tipo de estudio: Guideline / Observational_studies Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Ensayos Clínicos como Asunto / Selección de Paciente / Determinación de Punto Final / Antineoplásicos Tipo de estudio: Guideline / Observational_studies Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article